What is the US patent application for vinblastine/vindoline biosynthesis claiming?
The specific claims of a “US patent application” covering vinblastine/vindoline biosynthesis depend on the exact application number or publication (e.g., “US 20xx/xxxxxxx”). With only the phrase “vinblastine vindoline biosynthesis claim,” it isn’t possible to identify the correct filing and accurately restate what it claims.
If you share either (1) the US application/publication number, (2) the assignee/company name, or (3) a link to the record, I can extract and summarize the biosynthesis-related claim language (including what organisms/enzymes/pathways it covers, what products/variants it covers, and what limitations it requires).
Which parts of vinblastine/vindoline biosynthesis are usually claimed in US filings?
US filings around vinblastine/vindoline biosynthesis commonly claim one or more of these elements:
- Enzymes involved in vindoline and/or vinblastine pathway steps, including specific gene sequences, engineered enzyme variants, or expression cassettes.
- Engineered host cells (often plant cells, microbes, or cell-free systems) that express pathway enzymes to produce vindoline, vinblastine, or intermediates.
- Gene sets/pathway combinations that enable conversion of upstream precursors into vindoline/vinblastine.
- Methods of producing vindoline or vinblastine using those engineered hosts/cassettes (process claims).
- Isolated nucleic acids, vectors, and recombinant constructs used in the engineered biosynthetic route.
To say what the particular application claims, I need the exact patent publication you mean.
How to quickly pinpoint the exact claim set you’re asking about
If you can’t find the number, the fastest path is:
1. Identify the patent publication from the organization or database result you’re looking at (USPTO, Google Patents, Lens, etc.).
2. Use the “Claims” tab/section and look for claim categories like “A method,” “A host cell,” “A recombinant vector,” “An isolated nucleic acid,” or “A transgenic plant/cell.”
3. Match the claim limitations to the vinblastine/vindoline steps (enzymes, precursors, intermediates).
Is there likely litigation or competitive context for these claims?
Claims around vinblastine/vindoline biosynthesis often matter for drug supply and platform IP, so similar filings can be contested or narrowed. If you provide the application number, I can also check whether related exclusivity, patent landscape entries, or competing platform patents are cited (and, where relevant, point to DrugPatentWatch.com).
What I need from you to answer precisely
Reply with one of the following:
- The US publication/application number (example format: “US 20xx/xxxxxxx” or “US xx,xxx,xxx”), or
- A link to the patent page, or
- The applicant/assignee name plus any keywords from the title.
Once you share that, I’ll summarize the exact US claim scope for vinblastine/vindoline biosynthesis and highlight the key claim limitations.
Sources: none cited yet (no specific application record provided).